UCB, a global biopharmaceutical company, is presenting its research on generalized myasthenia gravis (gMG) at two annual meetings. It will present additional results from the MycarinG and RAISE studies on its drugs rozanolixizumab-noli and zilucoplan. Both drugs, recently approved by the US FDA and Japanese authorities, are under review by the European Medicines Agency for the treatment of adults with gMG. UCB is also assessing the drugs in pediatric patients with gMG.
“An Expensive Problem”: Cracking the Cyber Insurance Conundrum
Rampant ransomware attacks have hit the healthcare industry, with incidents increasing by more than 600%, costing an average of $10 million per breach. This has
